Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Condition:   Cardiomyopathy, Hypertrophic Obstructive
Intervention:   Drug: MYK-461
Sponsor:   MyoKardia, Inc.
Not yet recruiting - verified July 2016

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Condition:   Friedreich's Ataxia
Interventions:   Procedure: Cardiac magnetic resonance imaging (CMR);   Procedure: Exercise-stress test;   Procedure: Echocardiography (ECHO);   Procedure: Cardiac-related blood studies
Sponsors:   Annapurna Therapeutics;   Adverum Biotechnologies;   Weill Medical College of Cornell University
Recruiting - verified July 2016

Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy

Condition:   Pediatric Dilated Cardiomyopathy
Intervention:   Dietary Supplement: Water-soluble Ubiquinol
Sponsor:   Chung Shan Medical University
Not yet recruiting - verified July 2016

Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure

Conditions:   Heart Failure;   Insomnia;   Cardiomyopathy
Interventions:   Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I);   Behavioral: Heart Failure Self-Management Education
Sponsor:   Yale University
Completed - verified July 2016

Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients

Conditions:   Cardiomyopathy;   Cardiovascular Disease;   Heart Disease
Interventions:   Device: Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC);   Other: Standard Non-invasive Respiratory Depression Monitoring
Sponsor:   Emory University
Recruiting - verified July 2016

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Recruiting - verified July 2016

Prognostic Factors , Morbidity and Mortality in Patients With Muscular Dystrophies Admitted in ICU

Conditions:   Muscular Dystrophies;   Intensive Care (ICU) Myopathy
Sponsor:   Centre d'Investigation Clinique et Technologique 805
Active, not recruiting - verified July 2016

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

Condition:   Sickle Cell Disease
Interventions:   Other: Cardiac echography;   Other: Biological parameters;   Other: Clinical parameters
Sponsor:   Brugmann University Hospital
Completed - verified July 2016

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2016

Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy

Condition:   Cardiomyopathy, Dilated
Intervention:   Other: CMR using T1 mapping technique
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting - verified July 2016

Rhode Island Diastolic Dysfunction - Heart Failure

Conditions:   Heart Failure;   Cardiovascular Disease
Intervention:   Drug: Kuvan
Sponsors:   Providence VA Medical Center;   BioMarin Pharmaceutical;   Lifespan
Recruiting - verified July 2016

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Condition:   Primary Systemic (AL) Amyloidosis
Interventions:   Drug: NEOD001;   Other: Placebo
Sponsor:   Prothena Therapeutics Ltd.
Recruiting - verified July 2016

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Condition:   TTR-mediated Amyloidosis
Intervention:   Drug: Revusiran (ALN-TTRSC)
Sponsor:   Alnylam Pharmaceuticals
Active, not recruiting - verified July 2016

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Condition:   Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor:   Alnylam Pharmaceuticals
Completed - verified July 2016

Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure

Condition:   Ischemic Cardiomyopathy
Interventions:   Procedure: Percutaneous Coronary Intervention;   Drug: Drug Therapy for Heart Failure;   Device: Device Therapy for Heart Failure
Sponsors:   King's College London;   National Institute for Health Research, United Kingdom;   London School of Hygiene and Tropical Medicine (Clinical Trials Unit);   University of York;   Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified July 2016

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Conditions:   Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Sponsor:   Cure CMD
Recruiting - verified July 2016

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Condition:   Non-ischemic Dilated Cardiomyopathy
Interventions:   Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified July 2016

ACAM2000® Myopericarditis Registry

Conditions:   Myocarditis;   Pericarditis
Sponsor:   Sanofi Pasteur, a Sanofi Company
Active, not recruiting - verified July 2016

IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)

Conditions:   Heart Failure;   Coronary Artery Disease;   Ischemic Cardiomyopathy;   Non-ischemic Cardiomyopathy
Interventions:   Other: Advanced cardiac imaging;   Other: Standard Cardiac Imaging
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   The Finnish Funding Agency for Technology and Innovation (TEKES)
Recruiting - verified July 2016

The SMARTEX Heart Failure Study

Condition:   Heart Failure
Interventions:   Behavioral: Aerobic Interval Training;   Behavioral: Moderate continues training;   Behavioral: Recommendation of regular moderate exercise
Sponsors:   Norwegian University of Science and Technology;   University Hospital, Antwerp;   UMC Utrecht;   Technische Universität München;   Heartcenter Leipzig GmbH;   Bispebjerg Hospital;   St. Olavs Hospital;   Helse Stavanger HF
Completed - verified July 2016